Evidence map›Paper›PMID 41080089›Full record

ArticleJTO clinical and research reports2025

Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report.

Noa Amin, Thanika Ketpueak, Simon Jordan, Andrew G Nicholson, Yu Zhi Zhang, Sanjay Popat

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Noa AminLung Unit, Royal Marsden Hospital, London, United Kingdom.
Thanika KetpueakFaculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Simon JordanDepartment of Thoracic Surgery, Royal Brompton and Harefield NHS Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Andrew G NicholsonDepartment of Histopathology, Royal Brompton and Harefield NHS Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Yu Zhi ZhangDepartment of Histopathology, Royal Brompton and Harefield NHS Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Sanjay PopatLung Unit, Royal Marsden Hospital, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymic mucoepidermoid carcinoma (MEC) is a rare thymic carcinoma subtype. Current metastatic thymic carcinoma guidelines recommend first-line platinum-based chemotherapy. However, evidence suggests that MECs, including those of the lung and salivary gland, are chemorefractory, highlighting a more nuanced approach to systemic therapy decision-making. Here, we report a case of durable partial response to second-line lenvatinib in a patient with metastatic high-grade thymic MEC, refractory to first-line platinum-based chemotherapy, suggesting a potentially preferred first-line role for lenvatinib for this subtype.

Indexed as

Case reportLenvatinibMAML2 fusionMucoepidermoid carcinomaThymic carcinoma

Identifiers

PMID41080089
PMCPMC12514493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.